VIRUSCANProject ID: 731868
Optomechanics for Virology
Total cost:EUR 7 148 586,25
EU contribution:EUR 7 148 586,25
Call for proposal:FETPROACT-2016See other projects for this call
Funding scheme:RIA - Research and Innovation action
Viral infections diagnosis demands novel, cheaper and rapid technologies to overcome present constraints. Current gold standard for diagnosis of viral infections is based on pathogen-targeted nucleic acid identification; thus, it cannot discern infectious stages from latent ones and it demands time consuming adjustments when mutations occur or new emerging viruses are to be included in the diagnostic protocols. Lately, optomechanics has served to fundamental advancements in physics, from gravitational wave detection to the study of mechanical quantum ground states but it has not yet delivered its full applicability potential.
VIRUSCAN aims to apply frontier advancements in optomechanics to the biosensing and diagnostic fields and to create a new interdisciplinary research community with the goal to advance optomechanics, nanoelectromechanics, native mass spectrometry and biophysics towards clinical applications.
VIRUSCAN will provide a novel technology capable to identify viral particles and asses their infective potential through the characterization of two physical parameters: mass and stiffness. Stiffness of viral particles has been recently known to act as a regulator of their infectivity at different stages of the virus life cycle. In parallel, advancements in nanoelectromechanical systems have recently demonstrated that stiffness and mass information from nanoscale adsorbates can be disentangled. Targeting intrinsic physical properties of viral particles will allow developing an open platform that will tackle any virus and their mutations.
VIRUSCAN will have impact at all levels by: providing a personalized treatment to the patients, reducing the use of not effective antibiotics, increasing safety in blood transfusions, allowing a quick and trustworthy response to emergency situations (e.g. recent EBOLA in West Africa and the ZIKA in Brazil), reducing the spread of viral infections, reducing costs per analysis and screening of a wide range of pathogens.
EU contribution: EUR 1 248 082,50
EU contribution: EUR 856 486,25
RUE THOMAS MANN 5
EU contribution: EUR 1 079 262,50
2628 VK DELFT
EU contribution: EUR 1 098 870
CEA/DRT/LIST/DM2I – Digiteo Labs Saclay (bat. 565) Build. 565
91191 Gif sur Yvette
EU contribution: EUR 579 062,50
EU contribution: EUR 882 500
EU contribution: EUR 603 750
PLAZA CARLOS TRIAS BERTRAN 7
EU contribution: EUR 800 572,50
28TH KLM ATHINA LAMIA NATIONAL ROAD
19014 AFIDNES ATTIKIS